Affimed (NASDAQ: AFMD) reported Q3 EPS of €2.17, versus (€40.36) reported last year.

"Through the completion of our IPO and additional capital raised this past quarter, Affimed is well-positioned to achieve major value creation milestones for our clinical programs AFM13 and AFM11, as well as to complete preclinical development for AFM21, " said Dr. Adi Hoess, CEO of Affimed. "Affimed remains on target to provide an update on clinical data for both AFM13 and AFM11 during 2015. However, due to a slightly prolonged administrative process, the commencement of the AFM13 phase 2a study is expected to begin in early 2015."

Dr. Hoess added: "In the third quarter, we welcomed the addition of Berndt Modig to our Supervisory Board and look forward to the contribution of his financial experience."

For earnings history and earnings-related data on Affimed (AFMD) click here.